Ed Miseta - Chief Editor, Clinical Leader & Outsourced Pharma

Ed Miseta

Ed Miseta



Ed Miseta is the editor of ClinicalLeader.com. In this capacity he educates readers by providing the latest news and trends in the clinical research industry.

ED'S WORK

Regeneron Manages Clinical Costs In A Fast-Growing Organization
Regeneron Manages Clinical Costs In A Fast-Growing Organization Bari Kowal, VP and head of global clinical operations at Regeneron, says sponsors and CROs must partner to make clinical trial execution more efficient and cost-effective.  Continue Reading...
AbbVie Goes All-In On Wearables And Digital Technologies
AbbVie Goes All-In On Wearables And Digital Technologies Three years ago, AbbVie decided to stop talking about using digital technologies in clinical trials and start actually using them. The company then began deploying wearables in three clinical trials.  Continue Reading...
CRO Leadership Awards Move To Primetime
CRO Leadership Awards Move To Primetime If you are looking for a CRO to help take your molecule through clinical trials and the process of gaining regulatory approval, who do you turn to? It’ not like there is an Angie’s List for CROs.  Continue Reading...
Master Trial Protocols: Better For Pharma, Better For Sites
Master Trial Protocols: Better For Pharma, Better For Sites The primary benefit of master trial protocols for drug companies is the ability to concurrently evaluate multiple studies that may have different objectives, saving both time and money.  Continue Reading...
Navigating The Turbulent Waters From Discovery To Clinical
Navigating The Turbulent Waters From Discovery To Clinical “A partnering deal with a bigger pharma company would certainly help us through [the Phase 3] process,” explains Jeff Davidson, CEO of Keystone Nano, a company that develops nanoparticles that target solid tumors by going after cancer cells and leaving the normal cells intact.  Continue Reading...
Oncology Studies Show Pharma The Future Of Clinical Trials
Oncology Studies Show Pharma The Future Of Clinical Trials What does the future hold for oncology trials, which now comprise around 80 percent of all clinical research? We spoke to three experts who shared their insights into where the industry is headed in 2019 and beyond.  Continue Reading...
A Patient’s Journey To Join A CAR-T Cell Therapy Trial
A Patient’s Journey To Join A CAR-T Cell Therapy Trial Nicole Gularte is currently battling cancer for the 8th time. The last time she had to do so, it seemed a CAR-T cell therapy trial might be the solution. This article is about her long battle with cancer, the struggle to get into a CAR-T cell trial, and the ups and downs she has faced along the way. Her story is an inspiration to others.  Continue Reading...
A Small Biotech Takes On Some Big Clinical Trial Challenges
A Small Biotech Takes On Some Big Clinical Trial Challenges Evofem Biosciences is on the cusp of releasing a revolutionary birth control product. But before the FDA gives its approval, this small biopharma has to navigate two very different clinical trials.  Continue Reading...
Cannabis Trials Move Forward…But Lag In The U.S.
Cannabis Trials Move Forward…But Lag In The U.S. For researchers hoping to conduct clinical trials on cannabis-based products, the U.S. is not the most hospitable place. While other countries are legalizing the drug and conducting research on its possible medicinal uses, state and federal regulations on marijuana in the U.S. continue to stymie its use.  Continue Reading...
Science Driving Gene Therapy Development At bluebird bio
Science Driving Gene Therapy Development At bluebird bio For patients with sickle cell anemia, just getting through the day can be a struggle. Symptoms of the disease include vision problems, swelling of the hands and feet, and periodic episodes of pain that can last from a few hours to a few weeks. In this article Nick Leschly, CEO at bluebird bio, discusses the progress being made with its investigational gene therapy for sickle cell disease.  Continue Reading...
More From Ed Miseta